Updated:
HBM Genomics
HBM Genomics is a life sciences investment firm founded in 2014 in Palo Alto, California. It invests in early-stage companies and partners with founders on...
HBM Genomics
HBM Genomics is a life sciences investment firm founded in 2014 in Palo Alto, California. It invests in early-stage companies and partners with founders on strategy, hiring, funding, and scaling. HBM Genomics has made eight investments, including a Series A investment in Galatea Bio on March 27, 2025.
General information
Firm type
Private Equity
Year founded
2014
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Sector focus
Frequently asked questions
What investment stages does HBM Genomics typically target?
The firm focuses on seed and startup-stage rounds, typically leading or co-leading initial institutional investments in early-stage life-science and healthcare technology companies (per HBM Genomics' stated strategy, public record).
Which sectors does HBM Genomics explicitly avoid?
Publicly available information does not specify excluded sectors, but the firm concentrates exclusively on genomics, AI/ML in life sciences, and digital health, implying it avoids general industrial tech, real estate, or consumer-facing ventures.
Does HBM Genomics participate in fund commitments or only direct deals?
Available data suggests the firm makes direct equity investments in portfolio companies rather than committing to external fund vehicles, consistent with its described private equity direct-deal model.
How does HBM Genomics source proprietary deal flow?
The firm likely leverages relationships with university technology transfer offices and academic research centers, given its stated focus on early-stage ventures. No specific sourcing mechanisms have been publicly documented beyond this general approach.
Where is HBM Genomics based, and does it have additional offices?
The firm is headquartered in San Francisco, California. No additional office locations have been publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: